CN115400227A - JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途 - Google Patents
JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途 Download PDFInfo
- Publication number
- CN115400227A CN115400227A CN202110588280.2A CN202110588280A CN115400227A CN 115400227 A CN115400227 A CN 115400227A CN 202110588280 A CN202110588280 A CN 202110588280A CN 115400227 A CN115400227 A CN 115400227A
- Authority
- CN
- China
- Prior art keywords
- jund
- airway inflammation
- obstructive pulmonary
- gene
- pulmonary disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150021395 JUND gene Proteins 0.000 title claims abstract description 79
- 208000037883 airway inflammation Diseases 0.000 title claims abstract description 50
- 230000014509 gene expression Effects 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 37
- 239000012887 cigarette smoke extract Substances 0.000 claims abstract description 22
- 235000019504 cigarettes Nutrition 0.000 claims abstract description 11
- 239000000779 smoke Substances 0.000 claims abstract description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 18
- 238000003208 gene overexpression Methods 0.000 claims description 12
- 241000702421 Dependoparvovirus Species 0.000 claims description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 7
- 210000001552 airway epithelial cell Anatomy 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 230000002018 overexpression Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 3
- 102100023118 Transcription factor JunD Human genes 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 101100180395 Homo sapiens JUND gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100180396 Mus musculus Jund gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明提供了JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途,属于制药领域。本发明首次发现,JunD基因是气道炎症的核心基因,通过JunD过表达提高机体JunD的含量,能够有效缓解香烟烟雾提取物诱导的气道炎症,能够有效预防和治疗香烟烟雾诱导的小鼠慢性阻塞性肺疾病气道炎症。JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症,特别是慢性阻塞性肺疾病引起的气道炎症的药物中具有广阔的应用前景。
Description
技术领域
本发明属于制药领域,具体涉及JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症及慢性阻塞性肺疾病的药物中的用途。
背景技术
慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种具有气流阻塞为特征的慢性支气管炎和/或肺气肿,其以持续性气流受限为特征的疾病,是呼吸系统的常见病、多发病。COPD发病率高,吸烟是COPD最主要的危险因素,我国40岁以上人群的发病率达8.2%;COPD死亡率高,其目前是世界上第四大死亡原因。COPD临床症状主要表现为慢性咳嗽、咳痰、气短或呼吸困难、喘息和胸闷,随着疾病的进展还会发生气道炎症反应等,严重影响患者的生活质量,其高发病率、高致残率和高病死率也给患者及社会带来巨大的经济负担。因此,开发出能够有效防治COPD的药物具有重要意义。
虽然COPD一直受到广泛重视,但目前仍缺乏有效的防治方法。现普遍认为COPD是具有气流阻塞为特征的慢性支气管炎和/或肺气肿,而气道炎症尤其是小气道炎症是COPD的主要病变及发病的主要原因。然而,目前对其气道炎症的本质,特点及其炎症机制认识尚不十分明确。
目前,COPD临床治疗存在如下问题:单纯戒烟后COPD气道慢性炎症不会停止或逆转,而是持续性发展;单纯吸入糖皮质激素(ICS)虽然能缓解COPD患者的症状,延缓肺功能下降速度,但达不到理想的抗炎效果,不能阻止或逆转COPD的发展进程。因此,抑制气道炎症是治疗COPD的关键。
JunD是由JunD基因编码,由347个氨基酸组成的分子量约为35kD的激活剂蛋白-1(activating protein-1,AP-1)转录因子。JunD作为AP-1家族的一种转录因子,可以激活或抑制多种靶基因的表达,在生长发育过程中,JunD在各种细胞类型中都呈现出组成性表达。近20年的临床数据及分子生物学研究表明,JunD蛋白的功能受多个复杂过程调控,包括转录控制、转录后调节、蛋白质翻译后修饰及蛋白-蛋白相互作用等。研究发现,JunD基因表达的精细调控及JunD蛋白与其它蛋白之间的相互作用可调节细胞增殖、分化和凋亡等过程。JunD蛋白活性异常会导致肿瘤、代谢及病毒类疾病的发生。但是,目前还未见将JunD用来防治气道炎症或慢性阻塞性肺疾病的报道。
发明内容
本发明的目的在于提供JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症及慢性阻塞性肺疾病的药物中的用途。
本发明提供了JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途。
本发明JunD基因表达促进剂包括可以使得机体的JunD基因表达水平提高的任何物质,比如,JunD基因过表达质粒或JunD基因过表达腺相关病毒。
进一步地,所述气道炎症为慢性气道炎症。
进一步地,所述慢性气道炎症为香烟烟雾或香烟烟雾提取物诱导的慢性气道炎症。
进一步地,所述气道炎症为慢性阻塞性肺疾病引起的气道炎症。
本发明还提供了JunD或JunD基因表达促进剂在制备预防和/或治疗阻塞性肺疾病的药物中的用途。
进一步地,所述阻塞性肺疾病为慢性阻塞性肺疾病。
进一步地,所述慢性阻塞性肺疾病为香烟烟雾或香烟烟雾提取物诱导的慢性阻塞性肺疾病。
进一步地,所述JunD基因表达促进剂为JunD基因过表达质粒或JunD基因过表达腺相关病毒。
进一步地,所述药物能够降低炎症因子的表达。
进一步地,所述炎症因子为IL-1β、TNF-α;和/或,所述炎症因子为肺泡灌洗液和/或气道上皮细胞中的炎症因子。
进一步地,所述气道上皮细胞为支气管上皮细胞。
进一步地,所述药物为以JunD或JunD基因表达促进剂为活性成分,加上药学上可接受的辅料制得的制剂。
进一步地,所述制剂为口服制剂或注射制剂。
进一步地,所述口服制剂为汤剂、口服液、颗粒剂、胶囊剂、散剂、丸剂或片剂。
本发明首次发现,JunD基因是气道炎症的核心基因,通过JunD过表达提高机体JunD的含量,能够有效缓解香烟烟雾提取物诱导的气道炎症,能够有效预防和治疗香烟烟雾诱导的小鼠慢性阻塞性肺疾病气道炎症。JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症,特别是慢性阻塞性肺疾病引起的气道炎症的药物中具有广阔的应用前景,本发明为气道炎症和慢性阻塞性肺疾病提供了一个新的预防和治疗靶点。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1为各组细胞上清中炎症因子浓度的变化:与EV相比,***P<0.001,**P<0.01;与EV/CSE组相比,#P<0.05。
图2为各组小鼠BALF中炎症因子浓度的变化:与AAV9-EGFP相比,****P<0.0001;与AAV9-EGFP/CS相比,####P<0.0001。
具体实施方式
人源JunD基因过表达质粒,载体为pLVX-CMV,酶切位点为EcoRI/XhoI,抗生素类型Amp。
JunD基因序列为(NM_001286968):
AGGAGCCGCCGCCAGTGGAGGGCCGGGCGCTGCGGCCGCGGCCGGGGCGGGCGCAGGGCCGAGCGGACGGGGGGGCGCGGGCCCCCCGGGAGGCCGCGGCCACTCCCCCCCGGGCCGGCGCGGCGGGGGAGGCGGAGGATGGAAACACCCTTCTACGGCGATGAGGCGCTGAGCGGCCTGGGCGGCGGCGCCAGTGGCAGCGGCGGCAGCTTCGCGTCCCCGGGCCGCTTGTTCCCCGGGGCGCCCCCGACGGCCGCGGCCGGCAGCATGATGAAGAAGGACGCGCTGACGCTGAGCCTGAGTGAGCAGGTGGCGGCAGCGCTCAAGCCTGCGGCCGCGCCGCCTCCTACCCCCCTGCGCGCCGACGGCGCCCCCAGCGCGGCACCCCCCGACGGCCTGCTCGCCTCTCCCGACCTGGGGCTGCTGAAGCTGGCCTCCCCCGAGCTCGAGCGCCTCATCATCCAGTCCAACGGGCTGGTCACCACCACGCCGACGAGCTCACAGTTCCTCTACCCCAAGGTGGCGGCCAGCGAGGAGCAGGAGTTCGCCGAGGGCTTCGTCAAGGCCCTGGAGGATTTACACAAGCAGAACCAGCTCGGCGCGGGCGCGGCCGCTGCCGCCGCCGCCGCCGCCGCCGGGGGGCCCTCGGGCACGGCCACGGGCTCCGCGCCCCCCGGCGAGCTGGCCCCGGCGGCGGCCGCGCCCGAAGCGCCTGTCTACGCGAACCTGAGCAGCTACGCGGGCGGCGCCGGGGGCGCGGGGGGCGCCGCGACGGTCGCCTTCGCTGCCGAACCTGTGCCCTTCCCGCCGCCGCCACCCCCAGGCGCGTTGGGGCCGCCGCGCCTGGCTGCGCTCAAGGACGAGCCACAGACGGTGCCCGACGTGCCGAGCTTCGGCGAGAGCCCGCCGTTGTCGCCCATCGACATGGACACGCAGGAGCGCATCAAGGCGGAGCGCAAGCGGCTGCGCAACCGCATCGCCGCCTCCAAGTGCCGCAAGCGCAAGCTGGAGCGCATCTCGCGCCTGGAAGAGAAAGTGAAGACCCTCAAGAGTCAGAACACGGAGCTGGCGTCCACGGCGAGCCTGCTGCGCGAGCAGGTGGCGCAGCTCAAGCAGAAAGTCCTCAGCCACGTCAACAGCGGCTGCCAGCTGCTGCCCCAGCACCAGGTGCCCGCGTACTGAGTCCGCGCGCGGGGCGCATGCGCGGCCACCCTCCCCAAGGGGCGGGCTCGCGGGGGGGTGTCGTGGGCGCCCCGGACTTGGAGAGGGTGCGGCCCTGGGGACCCCCCCTCCCCGAGTGTGCCCAGGAACTCAGAGAGGGCGCGGCCCCCGGGGATTCCCCCCCCCCGAGGGTGCCCAGGACTCGACAAGCTGGACCCCCTGCTCCCGGGGGGGCGAGCGCATGACCCCCCCGCCCTCGCGCTGCCTCTTTCCCCCGCGCGGCCGCCCCGTGTTGCACAAACCCGCGCGTCTCGGCTGCCCCTTTGTACACCGCGCCGCGGAAGGGGGCTCCGAGGGGGCGCAGCCTCAAACCCTGCCTTTCCTTTACTTTTACTTTTTTTTTTTTTTCTTTGGAAGAGAGAAGAACAGAGTGTTCGATTCTGCCCTATTTATGTTTCTACTCGGGAACAAACGTTGGTTGTGTGTGTGTGTGTTTTCTTGTGTTGGTTTTTTAAAGAAATGGGAAGAAGAAAAAAAAATTCTCCGCCCCTTTCCTCGATCTCGCTCCCCCCTTCGGTTCTTTCGACCGGTCCCCCCTCCCTTTTTTGTTCTGTTTTGTTTTGTTTTGCTACGAGTCCACATTCCTGTTTGTAATCCTTGGTTCGCCCGGTTTTCTGTTTTCAGTAAAGTCTCGTTACGCCAGCTCGGCTCTCCGCCTCCTTCTTCCCCCGCCGGGGCCTGGCGGGCTGGGCGGGGCCTGGTTCGCTT。(SEQ ID NO.1)
小鼠JunD基因过表达腺相关病毒为GV598,载体信息为SP-Cp-MCS-EGFP-3Flag-SV40 Poly,血清型9型,基因名称:JunD(NM_010592)的克隆位点是AgeI/AgeI,购买于吉凯基因。
JunD基因序列为(NM_010592):
CAAGGCACAATGGCATATATTAGTCATCCAGAAGCCTGAGGTGAGATTTTGGGGGGTTCGGGAGGTCATTCTGGGGTACAGAGTGAGATTCTGTTTCAAAACGTCCCAATCCAGGGCCATAGGGTAGGCTTAGAAAGTAAACGTGACTGCACCCAAGTCGGACAGCCAGAGTGCCACACCGGGGAGAACAGACTCCCAACTCTCCTCTGACCTTCCTGGACACACACACACACAAAGCACAGATACCTACACAGACAAACACAGATACACAACCACACAGACAAACACACCAGCATGTAAAATAAAAACCGAGATCTGTAGGCCGAGGTTAAGAGACTCAGGCCTGTTACTGCCACACTTGGGAATATGAAACAGGGGGACTGAAGTTAAGTTCATGAATAGCGGAGTCTAGAGGATGAGATCCTGTCTTGACCCAAAACAAAGATTAAAAAAATTTTTTTTCACCGAGATCAAGAAAAAAACCTACAACTGATGGCTACCCTGGCTGCAGTTGGACTCCACACATCCCATCCTCAGTTTCCCCAAGGAAAAGGCAGGAGGTCAGCTTTTAGGGCGTTCGACTCCACCCTGTGAAACTGACAAGGAGCTAAGTAGTTGTGGGGACTCTCCAAGGGACCCTCCTCTGCCTCCCCCTTCCTGCCCACACCTGCCAGCTCCCAGCCGGAGGAACCCTGGCCGGCGCCCGGCCCCCGAGGGGCGTGCCTTCGGTGGGCGTGACGCGGGGCGTGGCTTCACAGAGGGCCTGGGTTTATGAGGCTCCACACATCACGCCACAGAAGTGCCAGAGACAGGGGAGAGATAGACGCACAGATGAGGTCCAGTTTGAGAAACAGAGAGGCAAGATCTAGAGGGAAGTAAAGAGGGGAGGAAGAGAAAGGGAGGAGAGGCAAGAAACAGCAGGGTAGGGACAGAGCCTGCCCGGCAATCCAAGCTGGGCGTGGTGACCCGGCCAAACCGCGTTCAGCCCCACCCCCATGACGTCAACCCACAATGCAGCGCGTTGTTGTGCCATGTAGCGAGCGTCGCTCTTGGCAACAGCGGCCGCCACCAGGCGAGGGCGTCCCGCTCCCGCCCCTTTATGCAAATCAACGACGTCACCTCGCGCCAATGGCGAGCGGGGGCGGTGAGCTCATCGCGGGGGCCGAGGCTATAAGAGTGCGCGCGGGCGGCGCGGGGCAGAGCGGCCGGCATCGGAGCCGGTCTGTACGGGCAGCGGACTGGGGGGCATACGGGGCCCCCCGGGGAGGCCGCGGCCACTCCCCCCGCCCCGGGGCCGAGCGCGGCGGGGGAGGTGGGGATGGAAACGCCCTTCTATGGCGAGGAGGCGCTGAGCGGCCTGGCTGCGGGTGCGTCGAGCGTCGCTGGTGCTACTGGGGCCCCCGGCGGTGGTGGCTTCGCGCCCCCGGGCCGCGCTTTCCCCGGGGCGCCCCCGACGAGCAGCATGCTGAAGAAAGACGCGCTGACGCTCAGCCTGGCGGAGCAGGGAGCGGCGGGATTGAAACCAGGGTCGGCCACTGCACCTTCTGCGCTGCGCCCCGACGGCGCCCCCGACGGGCTGCTGGCTTCGCCGGATCTTGGGCTGCTCAAACTCGCGTCGCCGGAGCTGGAGAGGCTGATCATCCAGTCCAACGGGCTGGTGACCACTACCCCGACCAGTACGCAGTTCCTCTACCCGAAGGTGGCAGCTAGCGAGGAGCAGGAGTTCGCCGAAGGCTTCGTCAAGGCGCTGGAGGACCTGCACAAGCAAAGCCAGCTGGGTGCGGCCACCGCGGCCACCTCAGGGGCTCCCGCGCCTCCCGCGCCCGCCGACCTGGCCGCCACCCCCGGGGCCACGGAGACCCCGGTCTACGCCAACCTGAGCAGTTTCGCGGGTGGCGCCGGGCCCCCTGGGGGCGCGGCCACCGTGGCTTTCGCCGCGGAGCCAGTGCCCTTCCCGCCGCCCCCGGGCGCGCTGGGGCCGCCGCCACCTCCGCATCCACCGCGCCTGGCCGCGCTCAAGGACGAGCCGCAGACCGTGCCGGACGTGCCGAGCTTCGGCGACAGCCCTCCGCTGTCGCCCATCGACATGGACACGCAAGAACGCATCAAGGCGGAGCGCAAGAGGCTGCGCAACCGCATCGCCGCCTCCAAATGCCGCAAGCGCAAGCTGGAGCGTATCTCGCGCCTGGAGGAGAAAGTCAAGACCCTCAAAAGCCAGAACACCGAGCTGGCGTCCACCGCCAGCCTGCTGCGCGAGCAGGTGGCGCAGCTCAAACAGAAAGTCCTCAGCCACGTCAACAGCGGCTGCCAGCTGCTGCCCCAGCACCAGGTCCCGGCGTACTGAGCCCGAGCGCGGGGCGCATGCGCGGACTAGCTGCGGTGGGGGGGCGCCCCGGACTCTTTCGAGACTCGGTGCCCCCGGACTCGACAAGCCGGACCCCCCTTAACTCTGGATGGGGAACCCGAGCGCACGACCCCCGCCCTCGCGCCGCCTCTCTACCCCCAGTCCTGCGCGTGGCTGCCCCTTTGTACCTCCGAGTAGGGGCTCTAAGGGGCGCGCAGCCTCACGCTCTGCCTTTCCTTTTTTTTTTGCCTTTTGGAAGAGAGAACGGGAGTGTCCGATTCCGCCCTATTTATGTTTCTACTCGGGAACAAACGTTGGTTGCGTGTTGAGTGTGTGTTTCCTTGTGTTGGTTTTTTAAAGAAACGGGAAGAAGAAAAAAAAAACCCTCTCCCCTCCCCCCCCCCCCGCTCTCTCTCCTCCCGACACCATCCCCTCTCTTTTTGTTTGGTTTTGTTTTGCTACGAGTCCACATTCCTGTTCCGTAATCCTTGGTTCGCCGGTTTTGTGTTTTCAGTAAAGTCTTCGTTACGCCAAAAAAAAAAAAAAAAAA。(SEQ ID NO.2)
实施例1 JunD过表达缓解气道炎症
1、实验方法
实验细胞:人正常支气管上皮细胞BEAS-2B。
本实施例通过转染人源JunD基因过表达质粒以构建JunD过表达细胞模型,转染空载体(EV)以构建对照细胞;利用香烟烟雾提取物(CSE)诱导构建气道上皮细胞炎症模型。
首先分成4组进行细胞干预,每组3次生物学重复:
(1)EV组:转染空载体12h;
(2)EV/CSE组:转染空载12h后,CSE干预24h;
(3)JunD组:转染JunD基因过表达质粒12h;
(4)JunD/CSE组:转染JunD基因过表达质粒12h后,CSE干预24h。
分组干预后,用酶联免疫吸附法(ELISA)测定各组细胞上清中炎症因子IL-1β、TNF-α的浓度。
2、实验结果
表1各组细胞上清中炎症因子浓度的变化(平均值±SD)
实验结果如表1和图1所示。可以看出,与EV组相比,EV/CSE组细胞上清中炎症因子IL-1β、TNF-α的浓度均显著升高(P<0.001,P<0.01),说明对正常气道上皮细胞用香烟烟雾提取物(CSE)刺激后能够成功诱导气道上皮细胞炎症。
与EV/CSE组相比,JunD/CSE组细胞上清中炎症因子IL-1β、TNF-α的浓度均显著降低(P<0.05),说明JunD过表达能够有效缓解香烟烟雾提取物(CSE)诱导的气道炎症。
上述实验结果表明,JunD基因是气道炎症的核心基因,通过JunD过表达提高机体JunD的含量,能够有效缓解香烟烟雾提取物诱导的气道炎症。
实施例2 JunD过表达缓解慢性阻塞性肺疾病气道炎症
1、实验方法
实验动物:SPF级雄性C57BL/6J小鼠,体重20-25克,8-10龄大。
本实施例通过尾静脉注射小鼠JunD基因过表达腺相关病毒(AAV-9-JunD)以构建JunD过表达小鼠模型,以尾静脉注射增强型绿色荧光蛋白(EGFP)作为腺相关病毒阴性对照小鼠;利用香烟烟雾(CS)诱导构建慢性阻塞性肺疾病气道炎症小鼠模型。
首先将小鼠随机分成4组进行干预,每组5只:
(1)AAV9-EGFP组:尾静脉注射3.14×107vg腺相关病毒阴性对照3周;
(2)AAV9-EGFP/CS组:尾静脉注射3.14×107vg腺相关病毒阴性对照3周,后连续熏烟4周;
(3)AAV9-JunD:尾静脉注射3.14×107vg JunD基因过表达腺相关病毒3周;
(4)AAV9-JunD/CS组:尾静脉注射3.14×107vg JunD基因过表达腺相关病毒3周,后连续熏烟4周;
分组干预后,用酶联免疫吸附法(ELISA)测定各组小鼠肺泡灌洗液(BALF)中炎症因子IL-1β、TNF-α的浓度。
2、实验结果
表2各组小鼠BALF中炎症因子浓度的变化(Mean±SD)
实验结果如表2和图2所示。可以看出,与AAV9-EGFP相比,AAV9-EGFP/CS组小鼠BALF中炎症因子IL-1β、TNF-α的浓度均显著升高(P<0.0001),说明AAV9-EGFP/CS组慢性阻塞性肺疾病气道炎症小鼠模型构建成功。
与AAV9-EGFP/CS组相比,AAV9-JunD/CS组小鼠BALF中的炎症因子IL-1β、TNF-α的浓度均显著降低((P<0.0001)。说明JunD过表达能够有效预防和治疗香烟烟雾诱导的小鼠慢性阻塞性肺疾病气道炎症。
上述实验结果表明,通过JunD过表达提高机体JunD的含量,能够有效预防和治疗香烟烟雾诱导的小鼠慢性阻塞性肺疾病气道炎症。
综上,本发明提供了JunD或JunD基因表达促进剂在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途。本发明首次发现,JunD基因是气道炎症的核心基因,通过JunD过表达提高机体JunD的含量,能够有效缓解香烟烟雾提取物诱导的气道炎症,能够有效预防和治疗香烟烟雾诱导的小鼠慢性阻塞性肺疾病气道炎症。JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症,特别是慢性阻塞性肺疾病引起的气道炎症的药物中具有广阔的应用前景。
SEQUENCE LISTING
<110> 四川大学华西医院
<120> JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途
<130> GYKH1094-2021P0113079CC21JS006
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 1929
<212> DNA
<213> 人工序列
<400> 1
aggagccgcc gccagtggag ggccgggcgc tgcggccgcg gccggggcgg gcgcagggcc 60
gagcggacgg gggggcgcgg gccccccggg aggccgcggc cactcccccc cgggccggcg 120
cggcggggga ggcggaggat ggaaacaccc ttctacggcg atgaggcgct gagcggcctg 180
ggcggcggcg ccagtggcag cggcggcagc ttcgcgtccc cgggccgctt gttccccggg 240
gcgcccccga cggccgcggc cggcagcatg atgaagaagg acgcgctgac gctgagcctg 300
agtgagcagg tggcggcagc gctcaagcct gcggccgcgc cgcctcctac ccccctgcgc 360
gccgacggcg cccccagcgc ggcacccccc gacggcctgc tcgcctctcc cgacctgggg 420
ctgctgaagc tggcctcccc cgagctcgag cgcctcatca tccagtccaa cgggctggtc 480
accaccacgc cgacgagctc acagttcctc taccccaagg tggcggccag cgaggagcag 540
gagttcgccg agggcttcgt caaggccctg gaggatttac acaagcagaa ccagctcggc 600
gcgggcgcgg ccgctgccgc cgccgccgcc gccgccgggg ggccctcggg cacggccacg 660
ggctccgcgc cccccggcga gctggccccg gcggcggccg cgcccgaagc gcctgtctac 720
gcgaacctga gcagctacgc gggcggcgcc gggggcgcgg ggggcgccgc gacggtcgcc 780
ttcgctgccg aacctgtgcc cttcccgccg ccgccacccc caggcgcgtt ggggccgccg 840
cgcctggctg cgctcaagga cgagccacag acggtgcccg acgtgccgag cttcggcgag 900
agcccgccgt tgtcgcccat cgacatggac acgcaggagc gcatcaaggc ggagcgcaag 960
cggctgcgca accgcatcgc cgcctccaag tgccgcaagc gcaagctgga gcgcatctcg 1020
cgcctggaag agaaagtgaa gaccctcaag agtcagaaca cggagctggc gtccacggcg 1080
agcctgctgc gcgagcaggt ggcgcagctc aagcagaaag tcctcagcca cgtcaacagc 1140
ggctgccagc tgctgcccca gcaccaggtg cccgcgtact gagtccgcgc gcggggcgca 1200
tgcgcggcca ccctccccaa ggggcgggct cgcggggggg tgtcgtgggc gccccggact 1260
tggagagggt gcggccctgg ggaccccccc tccccgagtg tgcccaggaa ctcagagagg 1320
gcgcggcccc cggggattcc ccccccccga gggtgcccag gactcgacaa gctggacccc 1380
ctgctcccgg gggggcgagc gcatgacccc cccgccctcg cgctgcctct ttcccccgcg 1440
cggccgcccc gtgttgcaca aacccgcgcg tctcggctgc ccctttgtac accgcgccgc 1500
ggaagggggc tccgaggggg cgcagcctca aaccctgcct ttcctttact tttacttttt 1560
tttttttttc tttggaagag agaagaacag agtgttcgat tctgccctat ttatgtttct 1620
actcgggaac aaacgttggt tgtgtgtgtg tgtgttttct tgtgttggtt ttttaaagaa 1680
atgggaagaa gaaaaaaaaa ttctccgccc ctttcctcga tctcgctccc cccttcggtt 1740
ctttcgaccg gtcccccctc ccttttttgt tctgttttgt tttgttttgc tacgagtcca 1800
cattcctgtt tgtaatcctt ggttcgcccg gttttctgtt ttcagtaaag tctcgttacg 1860
ccagctcggc tctccgcctc cttcttcccc cgccggggcc tggcgggctg ggcggggcct 1920
ggttcgctt 1929
<210> 2
<211> 2894
<212> DNA
<213> 小鼠
<400> 2
caaggcacaa tggcatatat tagtcatcca gaagcctgag gtgagatttt ggggggttcg 60
ggaggtcatt ctggggtaca gagtgagatt ctgtttcaaa acgtcccaat ccagggccat 120
agggtaggct tagaaagtaa acgtgactgc acccaagtcg gacagccaga gtgccacacc 180
ggggagaaca gactcccaac tctcctctga ccttcctgga cacacacaca cacaaagcac 240
agatacctac acagacaaac acagatacac aaccacacag acaaacacac cagcatgtaa 300
aataaaaacc gagatctgta ggccgaggtt aagagactca ggcctgttac tgccacactt 360
gggaatatga aacaggggga ctgaagttaa gttcatgaat agcggagtct agaggatgag 420
atcctgtctt gacccaaaac aaagattaaa aaaatttttt ttcaccgaga tcaagaaaaa 480
aacctacaac tgatggctac cctggctgca gttggactcc acacatccca tcctcagttt 540
ccccaaggaa aaggcaggag gtcagctttt agggcgttcg actccaccct gtgaaactga 600
caaggagcta agtagttgtg gggactctcc aagggaccct cctctgcctc ccccttcctg 660
cccacacctg ccagctccca gccggaggaa ccctggccgg cgcccggccc ccgaggggcg 720
tgccttcggt gggcgtgacg cggggcgtgg cttcacagag ggcctgggtt tatgaggctc 780
cacacatcac gccacagaag tgccagagac aggggagaga tagacgcaca gatgaggtcc 840
agtttgagaa acagagaggc aagatctaga gggaagtaaa gaggggagga agagaaaggg 900
aggagaggca agaaacagca gggtagggac agagcctgcc cggcaatcca agctgggcgt 960
ggtgacccgg ccaaaccgcg ttcagcccca cccccatgac gtcaacccac aatgcagcgc 1020
gttgttgtgc catgtagcga gcgtcgctct tggcaacagc ggccgccacc aggcgagggc 1080
gtcccgctcc cgccccttta tgcaaatcaa cgacgtcacc tcgcgccaat ggcgagcggg 1140
ggcggtgagc tcatcgcggg ggccgaggct ataagagtgc gcgcgggcgg cgcggggcag 1200
agcggccggc atcggagccg gtctgtacgg gcagcggact ggggggcata cggggccccc 1260
cggggaggcc gcggccactc cccccgcccc ggggccgagc gcggcggggg aggtggggat 1320
ggaaacgccc ttctatggcg aggaggcgct gagcggcctg gctgcgggtg cgtcgagcgt 1380
cgctggtgct actggggccc ccggcggtgg tggcttcgcg cccccgggcc gcgctttccc 1440
cggggcgccc ccgacgagca gcatgctgaa gaaagacgcg ctgacgctca gcctggcgga 1500
gcagggagcg gcgggattga aaccagggtc ggccactgca ccttctgcgc tgcgccccga 1560
cggcgccccc gacgggctgc tggcttcgcc ggatcttggg ctgctcaaac tcgcgtcgcc 1620
ggagctggag aggctgatca tccagtccaa cgggctggtg accactaccc cgaccagtac 1680
gcagttcctc tacccgaagg tggcagctag cgaggagcag gagttcgccg aaggcttcgt 1740
caaggcgctg gaggacctgc acaagcaaag ccagctgggt gcggccaccg cggccacctc 1800
aggggctccc gcgcctcccg cgcccgccga cctggccgcc acccccgggg ccacggagac 1860
cccggtctac gccaacctga gcagtttcgc gggtggcgcc gggccccctg ggggcgcggc 1920
caccgtggct ttcgccgcgg agccagtgcc cttcccgccg cccccgggcg cgctggggcc 1980
gccgccacct ccgcatccac cgcgcctggc cgcgctcaag gacgagccgc agaccgtgcc 2040
ggacgtgccg agcttcggcg acagccctcc gctgtcgccc atcgacatgg acacgcaaga 2100
acgcatcaag gcggagcgca agaggctgcg caaccgcatc gccgcctcca aatgccgcaa 2160
gcgcaagctg gagcgtatct cgcgcctgga ggagaaagtc aagaccctca aaagccagaa 2220
caccgagctg gcgtccaccg ccagcctgct gcgcgagcag gtggcgcagc tcaaacagaa 2280
agtcctcagc cacgtcaaca gcggctgcca gctgctgccc cagcaccagg tcccggcgta 2340
ctgagcccga gcgcggggcg catgcgcgga ctagctgcgg tgggggggcg ccccggactc 2400
tttcgagact cggtgccccc ggactcgaca agccggaccc cccttaactc tggatgggga 2460
acccgagcgc acgacccccg ccctcgcgcc gcctctctac ccccagtcct gcgcgtggct 2520
gcccctttgt acctccgagt aggggctcta aggggcgcgc agcctcacgc tctgcctttc 2580
cttttttttt tgccttttgg aagagagaac gggagtgtcc gattccgccc tatttatgtt 2640
tctactcggg aacaaacgtt ggttgcgtgt tgagtgtgtg tttccttgtg ttggtttttt 2700
aaagaaacgg gaagaagaaa aaaaaaaccc tctcccctcc cccccccccc gctctctctc 2760
ctcccgacac catcccctct ctttttgttt ggttttgttt tgctacgagt ccacattcct 2820
gttccgtaat ccttggttcg ccggttttgt gttttcagta aagtcttcgt tacgccaaaa 2880
aaaaaaaaaa aaaa 2894
Claims (10)
1.JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途。
2.根据权利要求1所述的用途,其特征在于:所述气道炎症为慢性气道炎症。
3.根据权利要求2所述的用途,其特征在于:所述慢性气道炎症为香烟烟雾或香烟烟雾提取物诱导的慢性气道炎症。
4.根据权利要求1~3任一项所述的用途,其特征在于:所述气道炎症为慢性阻塞性肺疾病引起的气道炎症。
5.JunD或JunD基因表达促进剂在制备预防和/或治疗阻塞性肺疾病的药物中的用途。
6.根据权利要求5所述的用途,其特征在于:所述阻塞性肺疾病为慢性阻塞性肺疾病。
7.根据权利要求6所述的用途,其特征在于:所述慢性阻塞性肺疾病为香烟烟雾或香烟烟雾提取物诱导的慢性阻塞性肺疾病。
8.根据权利要求1~7任一项所述的用途,其特征在于:所述JunD基因表达促进剂为JunD基因过表达质粒或JunD基因过表达腺相关病毒。
9.根据权利要求1~7任一项所述的用途,其特征在于:所述药物能够降低炎症因子的表达。
10.根据权利要求9所述的用途,其特征在于:所述炎症因子为IL-1β、TNF-α;和/或,所述炎症因子为肺泡灌洗液和/或气道上皮细胞中的炎症因子。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110588280.2A CN115400227A (zh) | 2021-05-28 | 2021-05-28 | JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110588280.2A CN115400227A (zh) | 2021-05-28 | 2021-05-28 | JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115400227A true CN115400227A (zh) | 2022-11-29 |
Family
ID=84155371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110588280.2A Pending CN115400227A (zh) | 2021-05-28 | 2021-05-28 | JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115400227A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009053683A2 (en) * | 2007-10-26 | 2009-04-30 | Medical Research Council | Treatment of inflammatory diseases |
CN106295244A (zh) * | 2015-06-05 | 2017-01-04 | 上海交通大学医学院附属瑞金医院 | 肿瘤诊断标志物的筛选方法、以该方法获得的乳腺癌肺转移相关基因及其应用 |
-
2021
- 2021-05-28 CN CN202110588280.2A patent/CN115400227A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009053683A2 (en) * | 2007-10-26 | 2009-04-30 | Medical Research Council | Treatment of inflammatory diseases |
CN106295244A (zh) * | 2015-06-05 | 2017-01-04 | 上海交通大学医学院附属瑞金医院 | 肿瘤诊断标志物的筛选方法、以该方法获得的乳腺癌肺转移相关基因及其应用 |
Non-Patent Citations (1)
Title |
---|
YANG D等: "GEO accession:GSE162902", NCBI GEO * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100379174B1 (ko) | DNA손상제및p53을포함하는조성물 | |
WO2016197592A1 (zh) | 一种长链非编码rna hnf1a-as1在制备治疗人体恶性实体瘤药物中的应用 | |
WO2021042944A1 (zh) | 肌肉靶向的微环dna基因治疗 | |
CN102796709A (zh) | 肝癌特异性基因-病毒及其应用 | |
WO2018193902A1 (ja) | マイクロrnaによるb型肝炎ウイルスに対する抗ウイルス効果 | |
Liu et al. | Tollip orchestrates macrophage polarization to alleviate intestinal mucosal inflammation | |
Yokoyama et al. | Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin | |
CN115400227A (zh) | JunD或JunD基因表达促进剂在制备预防和/或治疗气道炎症的药物中的用途 | |
BR112021003469A2 (pt) | genes sintéticos de feedback ativado, cassetes de seed match alvo e seus usos | |
CN113476606B (zh) | Upk1a-as1抑制剂在制备抗肿瘤药物中的应用 | |
WO2022105903A1 (zh) | 一种治疗肝纤维化的siRNA及其递送制剂 | |
WO2020238427A1 (zh) | 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用 | |
CN116724110A (zh) | 重组溶瘤病毒及其构建方法和用途 | |
CN111304316A (zh) | 基因Bmal1在制备检测治疗炎症性肠病的产品中的应用 | |
CN111840515A (zh) | Creg蛋白在巨核细胞成熟分化促血小板生成中的医药用途 | |
US7858590B2 (en) | Treatment of parkinson's disease and related disorders | |
CN110960546A (zh) | MicroRNAs在制备索拉非尼治疗肝癌的增强剂中的应用 | |
WO2024111743A1 (ko) | Gas5 억제제 및 smarca4 억제제를 유효성분으로 포함하는 간암 예방 또는 치료용 약학 조성물 | |
WO2021169034A1 (zh) | 转铁蛋白或过表达转铁蛋白在制备治疗和/或预防溃疡性结肠炎的药物中的应用 | |
CN111067892B (zh) | 青蒿琥酯在治疗原发性硬化性胆管炎模型小鼠的应用 | |
WO2023193705A1 (zh) | 西奥罗尼在抗胰腺癌中的用途 | |
WO2021213504A1 (zh) | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 | |
Zagozewski et al. | PDTM-28. AN OTX2-PAX3 SIGNALLING AXIS REGULATES GROUP 3 MEDULLOBLASTOMA CELL FATE | |
CN109939122B (zh) | 调控一碳代谢影响肿瘤干细胞干性的物质的应用 | |
WO2022267086A1 (zh) | 一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |